-
-
NCT Number
Not Available
-
Primary Citation
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment978% Female64.3%% White94.3%
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-USA-10Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)76
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2023-5295 : Individual-level and study-level predictors of neuropsychiatric symptom placebo response in Alzheimer?s Disease clinical trials
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2021-4683 : The effects of systemic anti-infective concomitant medications on progression of neurological diseases
- 2020-4324 : Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in AD, PD and DLB
- 2020-4323 : Identification of biomarkers associated with Alzheimer?s disease progression that correlate with responses to medications.
- 2017-1671 : Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and IPD NMA